The IU School of Medicine and Indiana CTSI are seeking a Director for the Disease and Therapeutic Response Modeling Program. The program's core focus is on the education of tomorrow's modeling and simulation scientists and on collaborative research projects utilizing quantitative models of disease that incorporate molecular mechanisms, clinical phenotypes, and drug exposure/effect relationships. The mission of the program is to span the translational research continuum, to expedite translational research by linking research discoveries and findings from bench to bedside, and to expand the implementation of new or novel therapies or therapeutic agents. The ultimate achievement is to enrich the standards of patient care by facilitating an individualization of therapeutic knowledge. This program is closely aligned with research sponsored by partners in academia and the pharmaceutical industry, such as Eli Lilly and Company and Takeda Pharmaceutical Company. A successful candidate will be able to build the strength of the program on these and other opportunities for collaboration.
The qualified candidate:
- Should have a PhD, PharmD, MD, or equivalent degree and be an experienced researcher with expertise in Pharmacometrics, Systems Pharmacology, Biomedical Engineering, or a related field.
- They will be expected to build and sustain a successful pharmacometrics/systems pharmacology training program through recruitment and mentoring of junior faculty and fellows, and by cultivating interdepartmental and external research collaborations.
- Importantly, the Director will have responsibility for cultivating research opportunities and collaborations that will lead to external funding and partnerships with researchers and clinicians within the IU School of Medicine, Indiana CTSI member institutions, and with other academic and industry partners.
- The successful candidate will have demonstrable competence through publications, grants, or extramural funding in potential areas of research collaboration such as but not limited to oncology; diabetes; neurosciences; cardiology; and pediatrics.
- The Director will also oversee a diverse yet integrated pharmacometrics training curriculum that bridges instruction in clinical pharmacology, biostatistics, bioinformatics, medical informatics, epidemiology, and genomics.
The Disease and Therapeutic Response Modeling Program is supported by resources from the Indiana CTSI with support of the Indiana Institute of Personalized Medicine and Center for Computational Biology and Bioinformatics with world-class, robust, reliable supercomputing and storage systems, advanced media and interactive visualization technologies. The Director will hold an appointment within the Division of Clinical Pharmacology, Department of Medicine.
Indiana University School of Medicine is the only allopathic medical school in the state of Indiana and the nation's largest. The school is one of the nation's premiere medical schools and is a leader and innovator in medical education, research, and clinical care. IUSM educates more than 1,600 medical and graduate degree students on nine campuses in Indiana. Indiana University Health, one of IUSMs clinical partners, has invested $150 million over five years in the Strategic Research Initiative, to enhance the institutions' joint capabilities in basic scientific investigation, translational research, and clinical trials.
IUSM is located in Indianapolis, the 12th largest city in the nation and the state capital. The cost of living is below the national average despite tremendous growth. The city enjoys a healthy arts community, with internationally recognized symphony, opera, and ballet companies and excellent museums, including the world's largest children's museum. Indianapolis is well-known for auto racing and is recognized internationally as an amateur sports center. It is home to professional football, men's and women's basketball, baseball, soccer, and hockey teams. Please visit http://www.indy.org or http://medicine.iupui.edu/AboutIndy to learn more about Indianapolis.